EDITORIAL
Published on 24 Nov 2021
Editorial: Immunotherapy as an Evolving Approach for the Treatment of Breast Cancer
doi 10.3389/fonc.2021.752689
- 1,709 views
- 2 citations
- Frontiers in Oncology
- Breast Cancer
- Research Topics
- Immunotherapy as an Evolving Approach for the Treatment of Breast Cancer
Immunotherapy as an Evolving Approach for the Treatment of Breast Cancer
33k
Total downloads
159k
Total views and downloads
Articles
ORIGINAL RESEARCH
Published on 08 Jun 2021
A Case Series of Metastatic Metaplastic Breast Carcinoma Treated With Anti-PD-1 Therapy
doi 10.3389/fonc.2021.635237
- 13,233 views
- 22 citations
HYPOTHESIS AND THEORY
Published on 23 Apr 2021
SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer
doi 10.3389/fonc.2021.638482
- 7,123 views
- 22 citations
ORIGINAL RESEARCH
Published on 17 Mar 2021
Clinical Outcomes for Patients With Metastatic Breast Cancer Treated With Immunotherapy Agents in Phase I Clinical Trials
doi 10.3389/fonc.2021.640690
- 4,707 views
- 9 citations
REVIEW
Published on 11 Mar 2021
The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy
doi 10.3389/fonc.2021.610303
- 32,846 views
- 174 citations
REVIEW
Published on 05 Mar 2021
Tackling Immune Targets for Breast Cancer: Beyond PD-1/PD-L1 Axis
doi 10.3389/fonc.2021.628138
- 6,404 views
- 13 citations
HYPOTHESIS AND THEORY
Published on 05 Mar 2021
Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer
doi 10.3389/fonc.2020.581801
- 5,274 views
- 18 citations
REVIEW
Published on 25 Feb 2021
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
doi 10.3389/fonc.2020.600573
- 38,930 views
- 122 citations
REVIEW
Published on 24 Feb 2021
Macrophages and Extracellular Matrix in Breast Cancer: Partners in Crime or Protective Allies?
doi 10.3389/fonc.2021.620773
- 8,956 views
- 61 citations
ORIGINAL RESEARCH
Published on 12 Feb 2021
ITM2A as a Tumor Suppressor and Its Correlation With PD-L1 in Breast Cancer
doi 10.3389/fonc.2020.581733
- 4,276 views
- 15 citations
REVIEW
Published on 26 Nov 2020
Lactate Metabolism and Immune Modulation in Breast Cancer: A Focused Review on Triple Negative Breast Tumors
doi 10.3389/fonc.2020.598626
- 6,728 views
- 43 citations
CLINICAL TRIAL
Published on 25 Nov 2020
PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer
doi 10.3389/fonc.2020.575978
- 2,880 views
- 7 citations
